Loncar Cancer Immunotherapy ETF (CNCR): Price and Financial Metrics ETF
CNCR Stock Price Chart Interactive Chart >
CNCR Price/Volume Stats - 7 Best ETFs for the NEXT Bull Market
Current price | $31.52 | 52-week high | $35.82 |
Prev. close | $31.20 | 52-week low | $12.00 |
Day low | $31.04 | Volume | 3,100 |
Day high | $31.75 | Avg. volume | 10,289 |
50-day MA | $33.46 | Dividend yield | 0.91% |
200-day MA | $29.05 |
Loncar Cancer Immunotherapy ETF (CNCR) ETF Bio
The investment objective of the Loncar Cancer Immunotherapy ETF seeks to replicate the Loncar Cancer Immunotherapy Index. The index was developed by a top biologist and includes large pharmaceutical and growth-oriented biotechnology firms that are focused on improving cancer treatments.
CNCR ETF Info
Issuer | Exchange Traded Concepts |
Expense Ratio | 0.79% |
Underlying Index | Loncar Cancer Immunotherapy Index |
Asset Class | Equity |
Sector | Health & Biotech ETFs |
Assets Under Management (AUM) | 47.28M |
Net Asset Value (NAV) | $31.52 |
Options? | Yes |
Total Holdings | 32 |
CNCR Top Holdings
Symbol | Company | % of Total |
IMAB | I-MAB-SPONSORED ADR | 0.06% |
BGNE | BEIGENE LTD | 0.05% |
NKTR | NEKTAR THERAP | 0.05% |
ALLO | Allogene Therapeutics | 0.04% |
ARGX | ARGENX SE - ADR | 0.04% |
RCUS | ARCUS BIOSCIENCES INC | 0.04% |
XNCR | Xencor Inc | 0.04% |
SRRK | Scholar Rock Holding Corp | 0.04% |
GILD | GILEAD SCI | 0.04% |
BMY | Bristol-Myers Squibb Co | 0.04% |
CNCR Price Returns
1-mo | -3.99% |
3-mo | -1.35% |
6-mo | 21.49% |
1-year | 46.91% |
3-year | 6.78% |
5-year | 46.90% |
YTD | -0.62% |
2020 | 36.53% |
2019 | 24.22% |
2018 | -20.65% |
2017 | 13.61% |
2016 | -25.63% |
CNCR Dividends
Ex-Dividend Date | Type | Payout Amount | Change | ||||||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!